The Effects of Microbiota Composition on Immunosuppression Protocols in Transplantation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-02-10

Study Completion Date

2021-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Solid organ transplantation is the treatment of choice for patients suffering from end-stage organ disease, including for chronic kidney failure. The implementation of effective immunosuppressive therapies has already significantly improved the prognosis for graft survival. However, these therapies are often associated with considerable inter- and intra-individual variability both in terms of response or in terms of pharmacokinetics. Innovative approaches must be considered, such as studying the involvement of intestinal microbiota in the pharmacology of these drugs.

The general aim of the study is therefore to relate the variabilities observed in the pharmacology (mainly pharmacokinetics) of immunosuppressive drugs used in renal transplantation (tacrolimus and mycophenolate mofetil) and the composition of the intestinal microbiota of renal transplant patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Long-Term Pharmacokinetics of Tacrolimus in Renal Recipients

NCT00411944

Renal Transplantation

COMPLETED

Comparison of the Two Immunosuppressive Regimens Based on Tacrolimus and Cyclosporine Following Kidney Transplantation

NCT00204191

Kidney Transplantation

UNKNOWN PHASE4

A Study Looking at Kidney Function in Kidney Transplant Recipients Who Are Taking Anti-rejection Medication Including Tacrolimus and With or Without Sirolimus.

NCT01363752

Kidney Transplantation

COMPLETED PHASE4

RCT Comparing Immunosuppressive Regimens in Elderly Renal Transplant Recipients

NCT03797196

Renal Transplant Recipients Elderly Patients Immunosuppression

ACTIVE_NOT_RECRUITING PHASE4

Gene Polymorphisms in Tacrolimus Drug Interactions

NCT00620841

Renal Transplantation

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Solid-organ transplantation often requires the implementation of a lifelong immunosuppressive therapy. A combination of tacrolimus (TAC), mycophenolate mofetil (MMF), together with steroids is currently used in over 60% of cases. In some patients however, these therapies are associated with high levels of variability, either in terms of response to treatments or in terms of pharmacokinetics, which remains unexplained. To address the issue, new approaches are being considered, in this study we will investigate the involvement of the intestinal microbiota in the pharmacology of these drugs. This is a particularly promising avenue for drugs with a low therapeutic index and large intra- and inter-individual pharmacokinetic variabilities such as tacrolimus and mycophenolate mofetil. Despite promising preliminary data for tacrolimus, the influence of the gut microbiota in these pharmacokinetic variabilities remains unclear, even less data are available about the involvement of the microbiota in the pharmacokinetics of mycophenolate mofetil.

We expect that this study will produce additional information on the effect of immunosuppression drugs on gut microbiota, and the relationship between microbiota composition and variabilities.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Kidney Transplant; Complications Immunosuppression Transplant Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Tacrolimus / Mycophenolate Mofetil

All patients receive maintenance immunosuppressive treatment of tacrolimus in combination with Mycophenolate Mofetil.

Tacrolimus

Intervention Type DRUG

Tacrolimus and Mycophenolate Mofetil are given in accordance with patient's current regimen

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tacrolimus

Tacrolimus and Mycophenolate Mofetil are given in accordance with patient's current regimen

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Mycophenolate Mofetil

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients within 1 to 8 years post transplantation
* Aged between 18 and 75 years old
* Patients receiving tacrolimus and mycophenolate mofetil as part of their immunosuppressive therapy
* French speaking
* BMI between 18 and 30.

Exclusion Criteria

* Use of tobacco
* Potential Alcohol problems (less than two positive answers to the CAGE questionnaire)
* Use of antibiotic medication within 3 months of the sample collection
* Use of laxative medication within 2 weeks of the sample collection
* Use of anti-fungal medication within 2 weeks of the sample collection
* Pregnant or lactating patients.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No